Individualisation of treatment regimens and goals is recommended for managing familial dyslipidaemias

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.23, Iss.7, 2007-07, pp. : 12-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Familial Dyslipidaemias: An Overview of Genetics, Pathophysiology and Management

By Hachem Sahar B.

Drugs, Vol. 66, Iss. 15, 2006-01 ,pp. : 1949-1969

Adis International

Access to resources Recommend Favorite

MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

By Burnett John R Watts Gerald F

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 2, 2007-02 ,pp. : 181-189

Informa Healthcare

Access to resources Recommend Favorite

Practical Treatment Guide for Dose Individualisation in Cancer Chemotherapy

By Canal P. Chatelut E. Guichard S.

Drugs, Vol. 56, Iss. 6, 1998-12 ,pp. : 1019-1038

Adis International

Access to resources Recommend Favorite

Editorial: (Pharmaco)Metabolomics in Drug Discovery and Individualisation of Treatment

Current Pharmaceutical Design, Vol. 23, Iss. 14, 2017-05 ,pp. : 2027-2027

Bentham Science Publishers

Access to resources Recommend Favorite

Early HIV treatment recommended

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 609, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite